Close
SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Prolia® (denosumab) - Risk of Unusual Thigh Bone Fractures
[November 21, 2012]

Prolia® (denosumab) - Risk of Unusual Thigh Bone Fractures

MISSISSAUGA, ON, Nov. 21, 2012, 2012 (Canada NewsWire via COMTEX) -- AMGEN Canada Inc., in association with Heath Canada, would like to inform you of new important safety information related to the risk of unusual thigh bone fractures associated with the use of PROLIA.

PROLIA (denosumab) is used to decrease the risk of broken bones in women who had their menopause and suffer from osteoporosis. It is specifically prescribed for women at high risk of breaking bones or those who are unable to take other osteoporosis medicines.

Some people have developed unusual fractures in their thigh bone while receiving PROLIA. These fractures are called "atypical fractures".


Atypical fractures are very rare. They can occur with minimal or no impact to the thigh area.

-- Atypical fractures have been reported very rarely, in less than 1 in 10,000 patients treated with PROLIA.

-- Patients with a potential fracture complain of dull, unusual aching pain in the thigh, hip or groin area.

-- Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh.

Amgen Canada has worked with Health Canada to update the safety information for PROLIA and has sent a letter to health care professionals to inform them of this new important safety information.

A copy of that letter is available on the Health Canada website (www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/index-eng.php). This information is also available at www.amgen.ca.

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious atypical fracture or other serious or unexpected side effects in patients receiving PROLIA should be reported to Amgen Canada Inc. or Health Canada.

Amgen Canada Inc.

6775 Financial Drive, Suite 100 Mississauga, Ontario L5N 0A4 Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655 Safety e-mail: safetycanada@amgen.com You can report any suspected side effect associated with the use of health products to Health Canada by: -- Calling toll-free at 1-866-234-2345; or -- Visiting MedEffect Canada's Web page onAdverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax For other health product inquiries related to this communication, contact Health Canada at: Marketed Health Products Directorate E-mail:MHPD_DPSC@hc-sc.gc.ca Telephone: 613-954-6522 Fax: 613-952-7738 SOURCE: Amgen Canada To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/November2012/21/c2344.html SOURCE: Amgen Canada For media inquiries, please contact: Michelle MacLeod Hill+Knowlton Strategies 416-413-4744 /Michelle.macleod@hkstrategies.ca

[ Back To TMCnet.com's Homepage ]





LATEST VIDEOS

DOWNLOAD CENTER

UPCOMING WEBINARS

MOST POPULAR STORIES





Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.